Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Iradimed (IRMD) Share-based Compensation (2016 - 2025)

Iradimed (IRMD) has disclosed Share-based Compensation for 13 consecutive years, with $696235.0 as the latest value for Q4 2025.

  • Quarterly Share-based Compensation rose 6.09% to $696235.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $2.9 million through Dec 2025, up 15.65% year-over-year, with the annual reading at $2.9 million for FY2025, 15.65% up from the prior year.
  • Share-based Compensation for Q4 2025 was $696235.0 at Iradimed, up from $666083.0 in the prior quarter.
  • The five-year high for Share-based Compensation was $826064.0 in Q1 2025, with the low at $121003.0 in Q2 2022.
  • Average Share-based Compensation over 5 years is $524169.4, with a median of $542406.0 recorded in 2023.
  • The sharpest move saw Share-based Compensation crashed 86.53% in 2021, then skyrocketed 369.79% in 2023.
  • Over 5 years, Share-based Compensation stood at $391784.0 in 2021, then grew by 8.88% to $426555.0 in 2022, then rose by 29.19% to $551064.0 in 2023, then rose by 19.1% to $656299.0 in 2024, then grew by 6.09% to $696235.0 in 2025.
  • According to Business Quant data, Share-based Compensation over the past three periods came in at $696235.0, $666083.0, and $730618.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.